What is Labviva?
Founded in 2007 and headquartered in Boston, MA, Labviva operates as a digital marketplace designed to streamline the procurement process for life science products. By integrating scientific content directly with product offerings from hundreds of brands and suppliers, Labviva creates a seamless purchasing experience for researchers. The platform's unique approach bridges the gap between scientific discovery and the necessary tools, fostering efficiency and accessibility within the life sciences sector. This strategic positioning in a critical industry segment has attracted substantial investment.
How much funding has Labviva raised?
Labviva has raised a total of $28M across 2 funding rounds:
Angel/Seed
$8M
Series A
$20M
Angel/Seed (2021): $8M with participation from Senator Investment Group, Glasswing Ventures, and B Capital Group
Series A (2023): $20M led by B Capital Group, Glasswing Ventures, Biospring Partners, and Senator Investment Group
Key Investors in Labviva
B Capital Group
B Capital is a venture capital firm that focuses on empowering entrepreneurs by investing in early and late-stage companies within the Technology, Healthcare, and Climate sectors. With over $8 billion in assets under management and a portfolio comprising more than 190 companies, B Capital aims to support founders throughout the company-building lifecycle.
Glasswing Ventures
Glasswing Ventures invests in visionary, early-stage founders who are leveraging AI and frontier technology to transform enterprise and security markets. The firm focuses on supporting startups that push the boundaries of possibility and offers deep technical expertise through its AI Palette and various frameworks.
Biospring Partners
Biospring specializes in partnering with technology-enabled, EBITDA-positive pharma services businesses that focus on innovation in manufacturing and clinical trial services. Their offerings include outsourced complex biomanufacturing, biologics manufacturing, cell therapy manufacturing, and modernized clinical trial services.
What's next for Labviva?
The recent major strategic investment signifies Labviva's transition into a scaling phase, likely aimed at expanding its platform capabilities, enhancing supplier and researcher networks, and potentially exploring new market segments within the life sciences. With substantial capital backing, the company is poised to further solidify its role as a key intermediary in the scientific supply chain. Future developments may include deeper integration of AI for personalized recommendations, advanced analytics for market insights, and broader adoption across global research institutions. The company's focus on creating a seamless purchasing experience is expected to drive continued growth and innovation.
See full Labviva company page
